Truist Financial’s Avidity Biosciences RNAM Stock Holding History

Truist Financial’s Portfolio RNAM Stock Details RNAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,627	Closed	-$202K	–	2844
2025 Q3	$202K	Buy	+4,627	New	+$187K	﹤0.01%	2555

Other funds holding RNAM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Truist Financial's RNAM Position: Q4 2025 in Review

Truist Financial sold out of Avidity Biosciences (RNAM) in Q4 2025, closing a stake of 4,627 shares — an estimated $202K sold.

Truist Financial first reported a position in RNAM in Q3 2025 and held it in 1 quarter. The position peaked at $202K in Q3 2025. 343 funds tracked by Wall St. Rank hold RNAM as of Q4 2025.

Truist Financial reported no remaining Avidity Biosciences position as of Q4 2025 after selling out during the quarter.
Truist Financial sold 4,627 Avidity Biosciences shares in Q4 2025, an estimated $202K.
Truist Financial first reported a position in Avidity Biosciences in Q3 2025 and held it in 1 quarter.
Truist Financial's Avidity Biosciences position peaked at $202K in Q3 2025.
343 funds tracked by Wall St. Rank held Avidity Biosciences as of Q4 2025.

Based on Truist Financial's 13F filing for Q4 2025, filed 2 Feb 2026.